Expression of androgen receptor and two androgen‐induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma <i>in situ</i> of the breast

González, Luis O.; Corte, M.D.; Junquera, Sara; Bongera, Miguel; Rodríguez, Juan Manuel Pinos; Vizoso, F

doi:10.1111/j.1365-2559.2007.02687.x

Cited by 22 publications

(17 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to previous reports [38], Yu et al [39] reported significantly higher AR expression in DCIS adjacent to invasive ductal carcinoma (IDC) than in specimens of pure DCIS or IDC (93.9% vs 79.4% and 72.5%; P00.046 and P<0.001 respectively). Based on these results and a previous study by Hanley et al [40] that demonstrated a significant loss of AR expression between high-grade DCIS and high-grade IDC (93% vs 55%; P<0.0001), there is speculation that AR may play a role in tumor dissemination, invasion, and progression, but further investigation in this subgroup is necessary.…”

Section: Androgen Receptor As a Prognostic Biomarkersupporting

confidence: 74%

The Androgen Receptor in Breast Cancer: Biology and Treatment Considerations

Gucalp

Traina

2011

Curr Breast Cancer Rep

View full text Add to dashboard Cite

The androgen receptor (AR) is expressed in 70-90% of invasive breast cancers. Despite the ubiquitous expression of AR in both primary and metastatic breast cancers, the clinical significance of this hormone receptor as a prognostic/predictive marker and its functional role in tumorigenesis remains poorly understood. This review summarizes the recent progress made in understanding the role of the AR as a prognostic/predictive marker in breast cancer and the underlying mechanisms by which the androgensignaling pathway may be involved in breast cancer pathogenesis. In addition, this review examines the available clinical data for the use of androgen-blocking agents in the treatment of breast cancer and explores the ongoing development of newer AR-targeted agents in this setting.

show abstract

Section: Androgen Receptor As a Prognostic Biomarkersupporting

confidence: 74%

The Androgen Receptor in Breast Cancer: Biology and Treatment Considerations

Gucalp

Traina

2011

Curr Breast Cancer Rep

View full text Add to dashboard Cite

show abstract

“…We speculate that local autocrine or paracrine androgen production is associated closely with the proliferation of AC, particularly in the early phases of tumour progression with a tendency toward stromal invasion. The difference in androgen synthesis in AC might explain why and how some AC lesions progress to massive invasion while other AC lesions remain in the non‐ or less‐invasive state 24 . In support of this hypothesis, there is evidence that AR/androgen up‐regulates MMPs, contributing to invasiveness via destruction of collagen IV 14,25 …”

Section: Discussionmentioning

confidence: 99%

Expression of 5α‐reductase in apocrine carcinoma of the breast and its correlation with clinicopathological aggressiveness

et al. 2012

View full text Add to dashboard Cite

Kasashima S, Kawashima A, Ozaki S & Nakanuma Y (2012) Histopathology 60, E51–E57 Expression of 5α‐reductase in apocrine carcinoma of the breast and its correlation with clinicopathological aggressiveness Aims: Apocrine carcinomas of the breast frequently lack oestrogen and progesterone receptors and often express androgen receptor. However, little is known about the role of androgen in apocrine carcinoma. Androgen‐producing enzymes, such as 5α‐reductase (5αR), which converts testosterone locally to the potent androgen dihydrotestosterone, have recently gained attention in studies of the intratumoural actions of androgens. The goal of this study was to examine 5αR expression and its relationship to other clinicopathological factors in apocrine carcinoma. Methods and results: Of 48 cases of infiltrating apocrine carcinoma, 30 cases (62.5%) were immunopositive for 5αR. Twenty‐seven of the 5αR‐positive cases were also positive for androgen receptor. In comparison to 5αR‐negative cases, 5αR‐positive cases showed clinicopathological aggressiveness characterized by significantly larger infiltrating tumour size (P = 0.001), higher frequency of lymphatic (P = 0.029) and vascular invasion (P = 0.009), higher histological grade (P = 0.048) and shorter recurrence‐free survival time (P = 0.047). No significant differences in nuclear grade, hormonal receptors, human epidermal growth factor receptor 2 (HER2) or p53 protein were detected between two groups. All five cases of intraductal apocrine carcinoma lacked 5αR. Conclusion: Approximately 60% of infiltrating apocrine carcinomas were immunopositive for 5αR. The 5αR‐positive apocrine carcinomas were clinicopathologically more aggressive than 5αR‐negative cases. Our findings suggest that autocrine androgen synthesis accelerates tumour aggressiveness in apocrine carcinoma.

show abstract

“…IHC was performed with an indirect immunoperoxydase method using the Benchmark XT from Ventana. Two antibodies directed against AR (a rabbit monoclonal primary antibody, clone SP107, prediluted, Ventana) [17,18] and FOXA1 (an affinity purified goat polyclonal antibody, HNF-3α/β (C-20), Santa Cruz biotechnology, dilution 1/200e) [19][20][21][22] were tested on the 14 TMAs.…”

Section: • • Patientsmentioning

confidence: 99%

Coexpression of Androgen Receptor and FOXA1 in Nonmetastatic Triple-Negative Breast Cancer: Ancillary Study from PACS08 Trial

et al. 2015

View full text Add to dashboard Cite

show abstract

Expression of androgen receptor and two androgen‐induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast

Abstract: AR expression may represent an independent predictive factor in DCIS of the breast.

Cited by 22 publications

References 54 publications

The Androgen Receptor in Breast Cancer: Biology and Treatment Considerations

The Androgen Receptor in Breast Cancer: Biology and Treatment Considerations

Expression of 5α‐reductase in apocrine carcinoma of the breast and its correlation with clinicopathological aggressiveness

Coexpression of Androgen Receptor and FOXA1 in Nonmetastatic Triple-Negative Breast Cancer: Ancillary Study from PACS08 Trial

Contact Info

Product

Resources

About